
: At the present time ketorolac is the only NSAID approved for intravenous and intramuscular use in humans. The half-life of naproxen is 12-15 hours compared to 4-6 hours for ketoralac, and naproxen has an antipyretic effect. A drug carrier system has been developed which allows for highly lipophilic compounds such as naproxen to be microencapsulated (MEC) for parenteral use. Intramuscular MEC naproxen could provide greater pain relief than ketoralac with a longer duration of action. MEC naproxen could also be given to reduce or replace opioid analgesics and reduce hyperthermia in patients unable to receive oral or rectal antipyretics. Since an assessment of the potential for local toxicity of a product intended for intramuscular injection is an important component of an initial drug development strategy, this research was conducted to determine the potential for myotoxicity from intramuscular MEC naproxen. Forty female Sprague Dawley rats were given intramuscular injections of 150 mg/kg MEC naproxen into the right gastrocnemius muscle with an equal volume of carrier polymer alone injected into the left. Animals were placed into four groups often for sacrifice at 24 hours, 72 hours, one week, and one month post-injection. Multiple tissue sections were cut, stainedwith hematoxylin and eosin, and examined under light microscopy for histopathologic changes. All samples were blinded before grading by a pathologist using the following scoring system: 0 = no damage; 1 = sparsely scattered hyalinized fibers and a localized inflammatory reaction; 2 = definite fiber destruction with the presence of macrophage digestion of muscle fibers and a mixed cellular infiltrate in some but not all sections examined; 3 = widespread muscle damage throughout the original specimen.
The Agency for Health Care Policy and Research (AHCPR) established guidelines for the use of meperidine (demerol), a common inpatient analgesic. These guidelines define standards of care for acute and chronic cancer pain management and address many of the problems with meperidine and its metabolite, normeperidine. The purpose of this study was to determine whether meperidine was prescribed in compliance with AHCPR guidelines, whether patients exhibited any adverse reactions to meperidine, and to determine the analgesic efficacy of meperidine. Three hundred inpatient charts were reviewed and identified meperidine as the primary analgesic in 157 nonobstetric inpatients. Age, sex, weight, dosing interval, route of administration, duration of meperidine use, serum chemistry values, primary diagnosis, associated medical conditions, and medications concurrently being taken with meperidine were the parameters analyzed. An interview was conducted to ascertain medical and drug history, chronicity of pain syndromes, analgesic drug history, and analgesic efficacy. A visual analog scale for pain (range = 0 to 10) and an analgesic satisfaction survey (range = 1 to 5) were used. Of 157 patients, 124 (79.8%) were in conflict with AHCPR guidelines. The most frequent conflict was found to be suboptimal dosing regimen and treatment of chronic pain. Often concurrent analgesics were given with the meperidine to achieve adequate analgesia. Higher analgesic satisfaction scores were noted when meperidine was given with concurrent analgesics. Meperidine also was administered to patients in renal failure or with medications contraindicated with meperidine use. No significant adverse effects were noted with meperidine use in this sample population other than an increased incidence of confusion in the elderly population.